

SUPPLEMENTARY TABLE 1: TARGET-MATCHED THERAPY IN PATIENTS WITH *PIK3CA* MUTATIONS (N=17)

ID	Age/ Sex	<i>PIK3CA</i> mutation	<i>KRAS</i> mutation	Prior therapies (N)	Targeted treatment	TTP (months)	ClinicalTrials.gov identifier
1	52/M	R1023Q	Unmutated	4	mTORC1 inhibitor (MTD)	1.3	NCT00877773
2	52/F	E545K	Unmutated	6	PI3K inhibitor (60% of MTD)	2.0	NCT00972686
3	57/M	H1047R	G12C	4	PI3K inhibitor (30% of MTD) + Paclitaxel + Carboplatin	1.7	NCT00756847
4	57/F	E542K	G12R	3	PI3K inhibitor (MTD)	1.8	NCT00726583
5	67/M	E545K	G12S	3	mTORC1 inhibitor (MTD)	1.2	NCT00877773
6	69/M	E545K	G12D	4	mTORC1 inhibitor (MTD)	4.6	NCT00877773
7	70/F	E545K	Q61H	7	PI3K inhibitor (MTD)	9.8	NCT00726583
8	50/F	H1047L	Unmutated	4	mTORC1 inhibitor (MTD) + Bevacizumab	0.6	NCT00610493
9	41/M	H1047R	G12V	5	mTORC1 inhibitor (MTD)	2.8	NCT00877773
10	43/F	E542K	G13D	2	PI3K inhibitor (45% of MTD)	3.5	NCT01219699
11	44/M	E545K	Unmutated	4	mTORC1 inhibitor (MTD) + Bevacizumab+ Liposomal Doxorubicin	3.1	NCT00761644
12	57/M	E545K	Unmutated	3	Akt inhibitor (MTD)	1.9	NCT00920257
13	67/M	G1049R	G12D	2	mTORC1 inhibitor (MTD) +Bevacizumab	1.5	NCT00610493
14	45/M	E542K	G12D	5	mTORC1 inhibitor (MTD)	1.4	NCT00877773
15	61/M	M1043V	G13D	4	mTORC1 inhibitor (MTD)	1.7	NCT00877773
16	69/F	Q546R	G12D	3	mTORC1 inhibitor (50% of MTD) +Docetaxel	1.3	NCT01054313
17	71/M	E545A	Unmutated	7	mTORC1 inhibitor (MTD) +Cetuximab	4.5	NCT00940381

MTD, maximum tolerated dose – indicates maximum tolerated dose, recommended phase II dose or FDA-approved dose of the PI3K/AKT/mTOR targeted agent